What Imetelstat Is and Why Telomerase Inhibition Matters in MDS

Imetelstat is a first-in-class telomerase inhibitor — a 13-mer oligonucleotide that competitively inhibits the RNA template component of telomerase (hTERC) — making it a mechanistically distinct therapy in a disease area historically dominated by erythropoiesis-stimulating agents (ESAs) and, more recently, luspatercept. Myelodysplastic syndromes (MDS) are a heterogeneous group of clonal hematopoietic stem cell disorders characterised by ineffective haematopoiesis, cytopenias, and a variable risk of progression to acute myeloid leukaemia (AML). In low-risk MDS, anaemia and transfusion dependence are the dominant clinical problems, and the failure of ESA therapy leaves a substantial unmet need.

Telomerase is aberrantly overexpressed in malignant hematopoietic progenitor cells in MDS, enabling the clonal population to maintain telomere length and evade replicative senescence. By inhibiting this enzyme, imetelstat targets the pathological clone driving ineffective erythropoiesis, rather than simply stimulating downstream erythroid differentiation as ESAs do. This upstream mechanism of action means imetelstat does not depend on functional erythroid precursors or intact TGF-beta signalling — a key distinction from luspatercept, which acts on the TGF-beta superfamily pathway to promote late-stage red cell maturation.

Geron Corporation, the originator of imetelstat, entered a collaboration with Johnson & Johnson (Janssen) to co-develop and commercialise the compound. This partnership brought substantial clinical and regulatory expertise to the programme, culminating in the submission and subsequent approval of the New Drug Application (NDA) for imetelstat — branded Rytelo — by the US FDA in June 2024. The approval was specifically for adult patients with low- to intermediate-1-risk MDS with transfusion-dependent anaemia requiring 4 or more red blood cell units over 8 weeks who have not responded to or have lost response to ESAs.

The IMerge Phase III Trial: Endpoints, Design, and Transfusion Independence Results

The IMerge Phase III trial is the pivotal study that supported imetelstat’s FDA approval, enrolling transfusion-dependent low- to intermediate-1-risk MDS patients who were relapsed or refractory to ESA therapy. The trial’s primary endpoint was the rate of 8-week transfusion independence (TI) — defined as no red blood cell transfusions for at least 8 consecutive weeks — a threshold recognised by both the FDA and EMA as clinically meaningful in this setting. IMerge met this primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in 8-week TI rate over placebo.

A critical secondary finding in IMerge was the durability of response. Among patients who achieved 8-week TI, a meaningful proportion maintained transfusion independence for 24 weeks or longer — a threshold considered indicative of sustained erythroid improvement rather than transient response. This durability signal is particularly important because it suggests imetelstat may be modifying the underlying clonal architecture of the disease, consistent with its mechanism of telomerase inhibition in malignant progenitors.

“Imetelstat’s durability of transfusion independence in IMerge Phase III — with a meaningful proportion of patients maintaining TI for 24 weeks or more — suggests the drug may be modifying the underlying malignant clone, not merely stimulating erythropoiesis downstream.”

The safety profile observed in IMerge was characterised primarily by reversible myelosuppression, particularly neutropenia and thrombocytopenia, consistent with imetelstat’s mechanism of inhibiting telomerase in rapidly dividing haematopoietic progenitors. Importantly, these cytopenias were generally manageable with dose modification and did not translate into excess rates of serious infection or bleeding in the trial population. Liver function test elevations were also observed and are listed as a monitoring requirement in the Rytelo prescribing information.

Imetelstat vs. Luspatercept: Mechanisms, Labels, and Patient Selection

Imetelstat and luspatercept both address transfusion-dependent anaemia in low-risk MDS, but they do so through entirely different biological pathways and carry meaningfully different approved labels. Luspatercept (Reblozyl), developed by Bristol-Myers Squibb and Acceleron Pharma, is a fusion protein that acts as a ligand trap for TGF-beta superfamily members — specifically GDF11 and activin B — to relieve inhibition of late-stage erythropoiesis. Its initial approval in MDS was specifically for patients with ring sideroblasts and transfusion-dependent anaemia who had an inadequate response to ESAs, as confirmed by the MEDALIST Phase III trial.

The most clinically significant competitive differentiator is the ring sideroblast requirement. Luspatercept’s initial MDS approval was restricted to patients with SF3B1 mutations or ring sideroblast positivity, reflecting the biology of the MEDALIST trial population. Imetelstat, by contrast, was studied and approved without a ring sideroblast restriction, meaning it is available to the broader ESA-refractory low-risk MDS population regardless of molecular or morphological subtype. This is a meaningful label advantage in a disease where ring sideroblast-negative patients historically had fewer options after ESA failure.

From a treatment sequencing perspective, the question of whether imetelstat and luspatercept can be used sequentially — or whether response to one predicts resistance to the other — is clinically important. Because their mechanisms are entirely distinct (clonal suppression via telomerase inhibition versus stimulation of erythroid differentiation via TGF-beta pathway modulation), there is a biological rationale for sequential use. However, prospective data on sequencing are currently limited, and prescribers must rely on mechanistic reasoning and retrospective analyses to guide decisions. According to guidance from NCCN and supported by data reviewed by FDA, both agents occupy the post-ESA space in low-risk MDS treatment algorithms, with patient-specific factors — including ring sideroblast status, prior therapy, and transfusion burden — guiding selection.

Patent Portfolio, FDA Approval, and the Commercial Landscape for Rytelo

Imetelstat’s intellectual property estate, held principally by Geron Corporation, covers the oligonucleotide composition, its formulation, and methods of use in haematologic malignancies. As a novel chemical entity with orphan drug designation in MDS, Rytelo benefits from multiple layers of market exclusivity: standard NDA exclusivity, orphan drug exclusivity (seven years in the US), and patent protection. The combination of these exclusivity mechanisms provides a meaningful runway for commercial development before generic or biosimilar competition becomes relevant.

The Geron–Johnson & Johnson collaboration structure assigned commercialisation rights to Johnson & Johnson (Janssen), which has the global infrastructure to support launch activities across the US and, pending regulatory review, international markets. The commercial launch of Rytelo in the US following the June 2024 FDA approval represents the culmination of more than two decades of development for imetelstat, which was originally investigated in solid tumours before the haematology programme demonstrated its clearest clinical signal. Analysts at firms tracking the MDS market have noted that the addressable population — low-risk MDS patients who are transfusion-dependent and ESA-refractory — numbers in the tens of thousands in the US alone, with global incidence data from WHO suggesting a broader international opportunity.

From a patent landscape perspective, the key risk for imetelstat’s commercial position lies not in near-term patent expiry but in the emergence of competing mechanisms. The MDS pipeline includes hypomethylating agent combinations, novel erythroid agents, and investigational telomerase pathway modulators, any of which could alter the treatment algorithm. PatSnap’s innovation intelligence platform enables R&D teams and competitive intelligence analysts to monitor patent filings, clinical trial registrations, and regulatory submissions across the MDS landscape in real time — a capability increasingly important as the post-ESA treatment space becomes more crowded.

Pipeline Implications and What the MDS Treatment Algorithm May Look Like

The approval of imetelstat reshapes the low-risk MDS treatment algorithm in a way that creates both opportunities and challenges for the broader pipeline. Prior to Rytelo’s approval, the post-ESA options in low-risk MDS were limited: luspatercept for ring sideroblast-positive patients, lenalidomide for del(5q) MDS, hypomethylating agents (azacitidine, decitabine) for higher-risk features, and supportive care with transfusions and iron chelation. Imetelstat now provides a mechanism-based option for the large segment of ESA-refractory, non-del(5q), non-ring-sideroblast patients who previously had no approved disease-modifying therapy.

Looking forward, several questions will shape how imetelstat integrates into clinical practice. First, biomarker-driven patient selection — particularly the use of telomere length and telomerase activity as predictive biomarkers — may allow more precise identification of patients most likely to respond, improving the real-world benefit-risk profile. Second, the question of combination therapy with hypomethylating agents or other novel agents is an active area of investigation, with the mechanistic rationale being that clonal suppression via telomerase inhibition combined with epigenetic reprogramming could produce additive or synergistic effects. Third, the competitive dynamics with luspatercept will evolve as label expansions, real-world evidence, and head-to-head or sequential studies accumulate.

For drug developers, patent attorneys, and R&D strategy teams, the imetelstat story illustrates the value of persistent investment in first-in-class mechanisms even when early clinical signals are modest. The telomerase inhibition hypothesis in haematologic malignancies took more than twenty years from concept to approved product. Monitoring the patent and clinical trial landscape for analogous emerging mechanisms — including other oligonucleotide-based approaches, novel erythroid differentiation agents, and clonal suppression strategies — is an increasingly important function for innovation intelligence teams. Resources such as WIPO‘s global patent database and PatSnap’s proprietary analytics layer provide the infrastructure to conduct this monitoring at scale.